Warfarin Management and Outcomes in Patients With Nonvalvular Atrial Fibrillation Within an Integrated Healthcare System

被引：0
|
作者：
An, JaeJin [1 ]
Niu, Fang [1 ]
Zheng, Chengyi [1 ]
Rashid, Nazia [1 ]
Mendes, Robert [1 ]
Dills, Diana [1 ]
Vo, Lien [1 ]
Singh, Prianka [1 ]
Bruno, Amanda [1 ]
Lang, Daniel [1 ]
Le, Paul [1 ]
Jazdzewski, Kristin [1 ]
Aranda, Gustavus [1 ]
机构：
[1] Western Univ Hlth Sci, Pomona, CA USA
来源：
CHEST | 2015年 / 148卷 / 04期
关键词：
D O I：
10.1378/chest.2259208
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
64A
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation
    Sherwood, Matthew W.
    Douketis, James D.
    Patel, Manesh R.
    Piccini, Jonathan P.
    Hellkamp, Anne S.
    Lokhnygina, Yuliya
    Spyropoulos, Alex C.
    Hankey, Graeme J.
    Singer, Daniel E.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Fox, Keith A. A.
    Califf, Robert M.
    Becker, Richard C.
    [J]. CIRCULATION, 2014, 129 (18) : 1850 - 1859
  • [2] Ximelagatran versus warfarin: A comparison of bleeding outcomes in patients with nonvalvular atrial fibrillation
    Douketis, JD
    Arneklev, K
    Goldhaber, S
    Spandorfer, J
    Halperin, F
    Horrow, J
    [J]. BLOOD, 2004, 104 (11) : 489A - 489A
  • [3] A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation
    Abdelhafiz, AH
    [J]. CLINICAL THERAPEUTICS, 2001, 23 (10) : 1628 - 1636
  • [4] Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin
    Schauer, DP
    Moomaw, CJ
    Wess, M
    Webb, T
    Eckman, MH
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 (12) : 1114 - 1119
  • [5] Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin
    Daniel P. Schauer
    Charles J. Moomaw
    Mark Wess
    Thomas Webb
    Mark H. Eckman
    [J]. Journal of General Internal Medicine, 2005, 20 : 1114 - 1119
  • [6] Rivaroxaban versus Warfarin: Effect on Healthcare Resource Utilization and Costs in Nonvalvular Atrial Fibrillation Patients
    Laliberte, Francois
    Crivera, Concetta
    Nelson, Winnie W.
    Olson, William H.
    Schein, Jeffrey
    Germain, Guillaume
    Lefebvre, Patrick
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 480 - 481
  • [7] Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation
    Scott, Katie A.
    Amirehsani, Karen A.
    [J]. JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2015, 27 (04) : 190 - 196
  • [8] Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
    Pink, J.
    Pirmohamed, M.
    Hughes, D. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 269 - 276
  • [9] Discontinuation/Interruption of Warfarin Therapy in Patients with Nonvalvular Atrial Fibrillation
    Spivey, Christina A.
    Qiao, Yanru
    Liu, Xianchen
    Mardekian, Jack
    Parker, Robert B.
    Phatak, Hemant
    Claflin, Abigail B.
    Kachroo, Sumesh
    Abdulsattar, Younos
    Chakrabarti, Anwesa
    Wang, Junling
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (07): : 596 - 606
  • [10] Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin.
    Schauer, DP
    Eckman, MH
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 : 200 - 200
12345